The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Autografts
Bleomycin
/ administration & dosage
Dacarbazine
/ administration & dosage
Disease-Free Survival
Doxorubicin
/ administration & dosage
Female
Hodgkin Disease
/ diagnostic imaging
Humans
Male
Middle Aged
Neoplasm Staging
Positron-Emission Tomography
Stem Cell Transplantation
Survival Rate
Vinblastine
/ administration & dosage
Absolute monocyte count
Hodgkin lymphoma
International Prognostic Score
Neutrophil lymphocyte ratio
PET
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
08
04
2019
accepted:
06
12
2019
pubmed:
25
12
2019
medline:
30
1
2020
entrez:
25
12
2019
Statut:
ppublish
Résumé
The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, stage IV, hemoglobin level, white blood cell and lymphocyte counts, and albumin level. Since the development of the IPS, there have been significant advances in therapy and supportive care. Recent studies suggest that the IPS is less discriminating due to improved outcomes with ABVD therapy. The aim of the present study was to asses if classic prognostic factors maintain their prognostic meaning at the time of response-adapted treatment based on interim PET scans. We evaluated the prognostic significance of IPS in the 520 advanced stage HL patients enrolled in the PET-guided, HD0801 trial in which PET2-positive patients underwent a more intense treatment with an early stem-cell transplantation after 2 cycles of ABVD. We observed that in these patients, the IPS completely loses its prognostic value together with all the single parameters that contribute to the IPS. Furthermore, neutrophils, monocytes, lymphocytes, and the ratio among them also no longer had any predictive value. We believe that the substantial improvement in survival outcomes in PET2-positive patients treated with early autologous transplantation could explain the complete disappearance of the residual prognostic significance of the IPS.
Identifiants
pubmed: 31872362
doi: 10.1007/s00277-019-03893-7
pii: 10.1007/s00277-019-03893-7
pmc: PMC6976582
doi:
Substances chimiques
Bleomycin
11056-06-7
Vinblastine
5V9KLZ54CY
Dacarbazine
7GR28W0FJI
Doxorubicin
80168379AG
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-282Commentaires et corrections
Type : ErratumIn
Références
J Clin Oncol. 2016 Apr 20;34(12):1376-85
pubmed: 26884559
J Clin Oncol. 2018 Feb 10;36(5):454-462
pubmed: 29360414
J Clin Oncol. 2012 Sep 20;30(27):3383-8
pubmed: 22869887
Mayo Clin Proc. 2015 Jun;90(6):756-64
pubmed: 26046410
Br J Haematol. 2015 Nov;171(4):530-8
pubmed: 26343802
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43
pubmed: 24811577
N Engl J Med. 1998 Nov 19;339(21):1506-14
pubmed: 9819449
N Engl J Med. 2016 Jun 23;374(25):2419-29
pubmed: 27332902
Blood. 2018 Mar 29;131(13):1456-1463
pubmed: 29437590
Lancet Haematol. 2016 Oct;3(10):e467-e479
pubmed: 27692305
J Clin Oncol. 2013 Feb 20;31(6):684-91
pubmed: 23182987
Ann Hematol. 2018 Jun;97(6):1009-1018
pubmed: 29442162
Hematol Oncol. 2017 Dec;35(4):561-566
pubmed: 27791277
J Clin Oncol. 2013 Feb 20;31(6):692-700
pubmed: 23182984
J Clin Oncol. 2016 Jun 10;34(17):2020-7
pubmed: 27069074
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182